FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
Sanome has secured Class IIb CE certification and MHRA approval for MEMORI - an AI-enabled warning system for the early prediction/prevention of healthcare‑associated infections (HAIs).
Read more here.
Driven by demand, Conexen are hoping to launch a new community in Manchester this October. They have an amazing team of local executives ready to go and excited to bring everybody in life sciences, biopharma and health together.
Contact them:…
Attendees
Sponsors and Exhibitors
Contact us